Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
about
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyA phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumorsPhase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyDose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumorsPopulation pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.Ependymoma: an update.Risk-adapted chemotherapy in childhood medulloblastoma.Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
P2860
Q33390957-8ECE1308-3656-4754-B322-8605D2BB80FBQ33405390-5B4FC64E-AB2B-4A4C-8178-D15CC368FDCEQ33780411-80A50226-4ABA-4F15-B693-BB171EC926AAQ33964850-84797F6B-2D94-423F-ABDD-D2A77772302EQ33979190-7E3F2A0A-581C-439E-8C46-45014BD20332Q34725699-09D353F9-648D-4B02-B7F3-0C356A2205D3Q35130636-EB3D7350-34FB-4D72-B8EA-478CC72B6612Q36467960-7A61E582-5C97-4339-95ED-E051D42C2EF6Q37617847-BFA2F67C-9D76-4E56-A7F3-8E896F06F895Q37873471-1101C9AB-0ACD-489F-A685-8EB264978C74Q39550844-79243687-8FF6-4F02-8D31-A53C3D1413D1Q47133403-0782BA30-2D98-4392-848A-F2FCD382E9B5Q49123833-276FD8E8-2284-4576-AB7A-3A01F6C1ECC7
P2860
Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase II study of oxaliplatin ...... brain tumor consortium study.
@ast
Phase II study of oxaliplatin ...... brain tumor consortium study.
@en
type
label
Phase II study of oxaliplatin ...... brain tumor consortium study.
@ast
Phase II study of oxaliplatin ...... brain tumor consortium study.
@en
prefLabel
Phase II study of oxaliplatin ...... brain tumor consortium study.
@ast
Phase II study of oxaliplatin ...... brain tumor consortium study.
@en
P2093
P50
P356
P1433
P1476
Phase II study of oxaliplatin ...... brain tumor consortium study.
@en
P2093
Adekunle M Adesina
Amar Gajjar
Burgess B Freeman
Christine Fuller
Clinton Stewart
James M Boyett
Mary K Danks
Michael L Hancock
Tina Young Poussaint
P304
P356
10.1002/CNCR.22241
P407
P577
2006-11-01T00:00:00Z